{"id":765006,"date":"2023-06-21T07:33:24","date_gmt":"2023-06-21T11:33:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/"},"modified":"2023-06-21T07:33:24","modified_gmt":"2023-06-21T11:33:24","slug":"cybin-to-participate-in-the-2023-maps-psychedelic-science-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/","title":{"rendered":"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Cybin to Participate in the 2023 MAPS Psychedelic Science Conference<\/b><\/p>\n<p>TORONTO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=53427063&amp;newsitemid=20230621688793&amp;lan=en-US&amp;anchor=Cybin+Inc.&amp;index=1&amp;md5=6901950d8b22962ccef9f2e5a7d7e9a2\">Cybin Inc.<\/a> (NEO:CYBN) (NYSE American:CYBN) (\u201c<b>Cybin<\/b>\u201d or the \u201c<b>Company<\/b>\u201d), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin\u2019s Chief Executive Officer, and Allison House-Gecewicz, Cybin\u2019s SVP of Clinical Operations, will be speaking at the Psychedelic Science 2023 Conference hosted the by Multidisciplinary Association for Psychedelic Studies (MAPS), taking place June 19-23, 2023 in Denver, Colorado. The details are as follows:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nMr. Drysdale will speak in a panel discussion titled \u201cLaying the foundation for a new ecosystem\u201d on Wednesday, June 21, 2023, at 12:00 p.m. MT.<\/p>\n<\/li>\n<li>\nMs. House-Gecewicz will speak at the Psychedelic Drug Pipeline Briefing Breakfast taking place on Thursday, June 22, 2023, at 8:00 a.m. MT.<\/p>\n<\/li>\n<\/ul>\n<p>\n\u201cWe are honored and excited to be speaking at one of the world\u2019s largest conferences on psychedelic healthcare,\u201d said Doug Drysdale, Chief Executive Officer of Cybin. \u201cWe look forward to engaging with healthcare professionals, scientists, policy makers, advocates, and other stakeholders within the psychedelics community, in conversations surrounding the latest developments in psychedelic healthcare.\u201d<\/p>\n<p>\n\u201cThe MAPS Psychedelic Science Conference is an opportunity to share the innovative clinical work that Cybin is carrying out to improve treatment options for mental health conditions, and to connect with individuals who share our goal of bringing psychedelic-based treatments to patients in need,\u201d said Allison House-Gecewicz, Cybin\u2019s SVP of Clinical Operations.<\/p>\n<p><b>About Cybin<\/b><\/p>\n<p>\nCybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.<\/p>\n<p>\nCybin\u2019s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.<\/p>\n<p>\nHeadquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cybin.com&amp;esheet=53427063&amp;newsitemid=20230621688793&amp;lan=en-US&amp;anchor=www.cybin.com&amp;index=2&amp;md5=309822a04b612f1b91de83f1375fa735\">www.cybin.com<\/a> or follow the team on Twitter, LinkedIn, YouTube and Instagram.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230621688793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230621688793\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230621688793\/en\/<\/a><\/span><\/p>\n<p><b>Investors &amp; Media:<br \/>\n<\/b><br \/>Gabriel Fahel<br \/>\n<br \/>Chief Legal Officer<br \/>\n<br \/>Cybin Inc.<br \/>\n<br \/>1-866-292-4601<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:irteam@cybin.com\">irteam@cybin.com<\/a> \u2013 or \u2013 <a rel=\"nofollow\" href=\"mailto:media@cybin.com\">media@cybin.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Colorado United States North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Mental Health Alternative Medicine Health Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230621688793\/en\/1824309\/3\/Cybin_Side_Logo_%28004%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Cybin to Participate in the 2023 MAPS Psychedelic Science Conference TORONTO&#8211;(BUSINESS WIRE)&#8211;Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (\u201cCybin\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin\u2019s Chief Executive Officer, and Allison House-Gecewicz, Cybin\u2019s SVP of Clinical Operations, will be speaking at the Psychedelic Science 2023 Conference hosted the by Multidisciplinary Association for Psychedelic Studies (MAPS), taking place June 19-23, 2023 in Denver, Colorado. The details are as follows: Mr. Drysdale will speak in a panel discussion titled \u201cLaying the foundation for a new ecosystem\u201d on Wednesday, June 21, 2023, at 12:00 p.m. MT. Ms. House-Gecewicz will speak at the Psychedelic Drug &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cybin to Participate in the 2023 MAPS Psychedelic Science Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765006","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cybin to Participate in the 2023 MAPS Psychedelic Science Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference TORONTO&#8211;(BUSINESS WIRE)&#8211;Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (\u201cCybin\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin\u2019s Chief Executive Officer, and Allison House-Gecewicz, Cybin\u2019s SVP of Clinical Operations, will be speaking at the Psychedelic Science 2023 Conference hosted the by Multidisciplinary Association for Psychedelic Studies (MAPS), taking place June 19-23, 2023 in Denver, Colorado. The details are as follows: Mr. Drysdale will speak in a panel discussion titled \u201cLaying the foundation for a new ecosystem\u201d on Wednesday, June 21, 2023, at 12:00 p.m. MT. Ms. House-Gecewicz will speak at the Psychedelic Drug &hellip; Continue reading &quot;Cybin to Participate in the 2023 MAPS Psychedelic Science Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-21T11:33:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230621688793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference\",\"datePublished\":\"2023-06-21T11:33:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\\\/\"},\"wordCount\":458,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230621688793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\\\/\",\"name\":\"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230621688793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-06-21T11:33:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230621688793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230621688793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference - Market Newsdesk","og_description":"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference TORONTO&#8211;(BUSINESS WIRE)&#8211;Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (\u201cCybin\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin\u2019s Chief Executive Officer, and Allison House-Gecewicz, Cybin\u2019s SVP of Clinical Operations, will be speaking at the Psychedelic Science 2023 Conference hosted the by Multidisciplinary Association for Psychedelic Studies (MAPS), taking place June 19-23, 2023 in Denver, Colorado. The details are as follows: Mr. Drysdale will speak in a panel discussion titled \u201cLaying the foundation for a new ecosystem\u201d on Wednesday, June 21, 2023, at 12:00 p.m. MT. Ms. House-Gecewicz will speak at the Psychedelic Drug &hellip; Continue reading \"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-21T11:33:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230621688793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference","datePublished":"2023-06-21T11:33:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/"},"wordCount":458,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230621688793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/","name":"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230621688793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-06-21T11:33:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230621688793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230621688793r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cybin-to-participate-in-the-2023-maps-psychedelic-science-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cybin to Participate in the 2023 MAPS Psychedelic Science Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765006"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765006\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}